| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 10, 2026 | Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines | |
| Aug 12, 2026 | Vedanta Biosciences Secures $60M for Groundbreaking Microbiome Therapy | Vedanta Biosciences secured $60 million in new capital. The Cambridge, MA biopharma advances microbiome-based oral therapies. Funds fuel its pivotal Phase 3 RESTORATiVE303 study. This trial targets recurrent C. difficile infection. Investor... |
| Aug 6, 2026 | Vedanta Biosciences Raises $60M in Funding | Vedanta Biosciences, a Cambridge, MA-based provider of microbiome-based oral therapies for gastrointestinal diseases, raised $60M in funding.
The round was led by AMR Action Fund and BNP Paribas Asset Management Alts, with participation fro... |
| Aug 6, 2026 | ReCode Therapeutics Receives Investment From Cystic Fibrosis Foundation | ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, received an investment from Cystic Fibrosis Foundation (CF Foundation).
The amount of the deal was not disclosed.
The company intends to use the funds to ... |
| Jun 16, 2026 | SpliSense Raises Up to $13M in Funding | SpliSense, a Jerusalem, Israel-based clinical-stage biotechnology company, raised up to $13M in funding.
The round was led by Cystic Fibrosis Foundation.
The company intends to use the funds to support the continued clinical development of ... |
| May 7, 2026 | Anagram Therapeutics Raises $250 Million From Blackstone Life Sciences To Advance Oral Enzyme Replacement Therapy | Blackstone Life Sciences announced a $250 million investment in Anagram Therapeutics, a clinical-stage biopharmaceutical company developing oral enzyme replacement therapies for people with exocrine pancreatic insufficiency associated with ... |
| Mar 3, 2026 | Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease Targets | Antiverse, an AI-driven techbio company specializing in de novo antibody design for challenging drug targets, has raised $9.3 million in Series A financing to accelerate the development of therapeutic antibodies aimed at historically undrug... |
| Oct 14, 2025 | How a reluctant CEO conquered imposter syndrome to turn a biotech profitable | CNBC is now accepting nominations for the 2026 Changemakers list. Learn more and submit a nomination by Nov 21.
Katherine Stueland, CEO at genetics testing and genomics company GeneDx, turned a financially challenged firm profitable within ... |
| Sep 29, 2025 | ReCode Therapeutics Raises Over $29M in Additional Financing | ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, raised over $29M in additional funding.
Backers were undisclosed.
It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) an... |
| Aug 8, 2025 | SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-Medicine | Copenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infe... |
| Aug 8, 2025 | Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer | Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat ant... |
| Aug 7, 2025 | SNIPR BIOME Raises EUR 35M in Series B Funding | SNIPR BIOME, a Copenhagen, Denmark-based company improving the development of microbial CRISPR-medicine, raised EUR 35M in Series B funding.
Backers included Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovati... |
| Mar 25, 2025 | Owlstone Medical announces investment of up to $2.3 Million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detection in Cystic Fibrosis patients | Test to be developed for Pseudomonas aeruginosa detection in patients with cystic fibrosis suitable for both detection of new cases and monitoring of chronic infection
Support to demonstrate proof of principle in chronic infection to be pro... |
| Nov 11, 2024 | Battling TB: A Global Call to Action | Tuberculosis (TB) is a silent killer. It creeps through communities, often unnoticed until it’s too late. The World Health Organization (WHO) estimates that TB claims over 1.5 million lives each year. This disease, which has plagued humanit... |
| Nov 11, 2024 | TB Alliance Joins Indonesia's High-Level Meeting on TB | Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic
BALI, Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts... |
| Aug 28, 2024 | Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer | Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases
Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly c... |
| Jul 10, 2024 | Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions | CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and promotions. Today's personnel announcement acco... |
| Mar 25, 2024 | Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB | AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million... |
| Dec 9, 2023 | Health | $200,000-a-year cystic fibrosis medication deemed “affordable” by Colorado review board because of coupons | Colorado’s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn’t qualify as “unaffordable,” based on the drug’s benefits to patients and the availability of coup... |
| Nov 3, 2023 | State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta | I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic fibrosis drug Trikafta. Five years later, the... |
| Jun 23, 2023 | Pittsburgh Financial Group CEO Andrew Pravlik Makes Generous Donation to the Cystic Fibrosis Foundation | "I am honored to support the Cystic Fibrosis Foundation and join forces with outstanding young professionals like Channing Powell."
PITTSBURGH (PRWEB) June 23, 2023
The Cystic Fibrosis Foundation, the world’s leader in the search ... |
| Feb 21, 2023 | Coyote Hole Craft Beverages Launches Adventure Series Cider Line for a Cause | Coyote Hole Craft Beverages Announces their Adventure Series Hard Cider Line
Coyote Hole is launching a new hard cider series with consumer cost in mind while donating a portion of every cider to the Cystic Fibrosis Foundation MINERAL, VIRG... |
| Feb 13, 2023 | Claire’s Place Foundation Executive Director to Speak at BreatheCon 2023 | “I am honored to be a presenter at BreatheCon 2023,” said Claire’s Place Foundation Executive Director Melissa Yeager.
LOS ANGELES (PRWEB) February 13, 2023
Claire’s Place Foundation, a non-profit organization providing support to children ... |
| Nov 16, 2022 | LifeArc funds home monitoring trials for people with chronic respiratory conditions | LifeArc is partnering with researchers at Royal Papworth Hospital NHS Foundation Trust to fund new UK-wide trials investigating if machine learning technology can transform how people living with chronic respiratory conditions manage their ... |
| Jun 9, 2022 | Poole completes ‘24 Hour Fitness Challenge for Cystic Fibrosis’ | ELLICOTTVILLE — He’s done it again.
Local fitness instructor Bradley Poole completed his “24 Hour Fitness Challenge for Cystic Fibrosis” on Saturday at his gym, Warrior Fitness & Wellness in Ellicottville.
Beginning Friday at 11 a.m. an... |
| Jun 2, 2022 | Poole readies for ‘24-Hour Fitness Challenge for Cystic Fibrosis’ | ELLICOTTVILLE — Bradley Poole, local fitness instructor, is hosting a “24 Hour Fitness Challenge for Cystic Fibrosis” to benefit the cause.
This year’s event will take place Friday and Saturday at Warrior Fitness & Wellness, his gym at ... |
| Apr 19, 2022 | Sionna unveils with $111M series B to pursue quest for 'holy grail' cystic fibrosis target | After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex Pharmaceuticals.
Having raised roughly $150 m... |
| Mar 16, 2022 | Chiesi USA donates more than $815,000 to local communities and nonprofits in 2021 | CARY, N.C., March 16, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, contributed more than $815,000 in 2021 through its Chiesi in the Community (CITC) corporate social responsibility (C... |
| Mar 2, 2022 | Rediscovering a language of healing that doesn’t require ‘cure’ | I am a biotech investor and entrepreneur. But more central to my worldview is that I am someone who lives with a rare genetic disease. This has sensitized me to the flippant ways that excited scientists and entrepreneurs toss around notions... |
| Jan 25, 2022 | How mRNA And DNA Vaccines Could Soon Treat Cancers, HIV, Autoimmune Disorders And Genetic Diseases | wp_booster error:
td_api_base::get_key : a component with the ID: single_template_2 Key: show_featured_image_on_all_pages is not set.
/home/r8qkakm4wchc/public_html/wp-content/plugins/td-composer/legacy/common/wp_booster/td_api.php (rara-er... |
| Jan 25, 2022 | How mRNA And DNA Vaccines Could Soon Treat Cancers, HIV, Autoimmune Disorders And Genetic Diseases | wp_booster error:
td_api_base::get_key : a component with the ID: single_template_2 Key: show_featured_image_on_all_pages is not set.
/var/web/site/public_html/wp-content/plugins/td-composer/legacy/common/wp_booster/td_api.php (rara-error) ... |
| Jan 7, 2022 | ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis | YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides... |
| Jan 6, 2022 | Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations | Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today announced that its wholly-owned subsidiar... |
| Jan 6, 2022 | ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis | YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides... |
| Jan 4, 2022 | BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation | BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive ... |
| Nov 9, 2021 | ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis | YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides... |
| Nov 9, 2021 | ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis | YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides... |
| Mar 9, 2021 | AMERICAN AIRLINES GROUP INC.
American Airlines : 36th Annual Celebrity Ski Event Goes Virtual, Raising Critical Funds for the Cystic Fibrosis Foundation | FORT WORTH, Texas ― For 36 years, American Airlines has partnered with the Cystic Fibrosis Foundation to host Celebrity Ski Weekend. While this year's event shifted from the slopes of Beaver Creek, Colorado, to a virtual setting, the import... |
| Dec 4, 2020 | A Tennessee baby born from a nearly 28-year-old frozen embryo broke a world record previously set by her own sister | Molly Everette Gibson was born from an embryo less than two years younger than her mum Tina. Courtesy of Haleigh Crabtree Photography
Tina Gibson’s one-month-old daughter, Molly Everette, was born from a donated embryo frozen less than two ... |
| Sep 8, 2020 | Health care conferences should embrace patients as collaborators | Health care conferences like the North American Cystic Fibrosis Conference are as much professional events and critical evaluators of progress as they are times to connect with old friends and make new ones. Almost universally, they are mis... |
| Jul 13, 2020 | Poole finishes giving Cattaraugus County the run-around | In the hopes of raising $100,000 for the Cystic Fibrosis Foundation, Western New York Chapter, and awareness about the disease, Bradley Poole of Salamanca gave Cattaraugus County the run-around last week.
Running For a Cure, a trek that tot... |
| Jul 5, 2020 | Running 266 miles across Catt. County for a cause | ELLICOTTVILLE — Bradley Poole has been prepping for a run of his lifetime.
From July 5 to 11, the local fitness trainer will be running 266 miles across Cattaraugus County to raise funds for the Cystic Fibrosis Foundation, Western New York ... |
| Mar 29, 2020 | Salamanca man giving the run-around to raise funds for Cystic Fibrosis | Every day we hear about regular people who do something that seems utterly unattainable to the rest of us, something that we’d never see ourselves doing.
Bradley Poole, 32, of Salamanca, is one of those people. He wants to run 266 miles aro... |
| Oct 22, 2019 | CD47 player Trillium chops discovery efforts and 40% of staff; Brii Bio inks deal to bring antibiotics to China | → One month into his tenure at Canadian microcap biotech Trillium, Jan Skvarka is bringing out the ax as he sorts out the development plans for its CD47 drugs. The restructuring will see the discovery research unit nixed a... |
| Nov 5, 2018 | One number keeps me from taking part in cystic fibrosis trials. That’s wrong | I’ve known since I was a little girl that cystic fibrosis is a disease that only gets worse. Every day it destroys lung cells and tightens the small airways in my chest, taking me closer to the point when my ravaged lungs stop working. I’ve... |
| Aug 2, 2018 | Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients | ATLANTA – Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, on... |
| Aug 1, 2018 | Discovery of unknown lung cell points to new target for cystic fibrosis medicines | The researchers set out to take a census of all the cells that line our airway, a taxonomy of the tissue made possible by new technology. Perhaps, they thought, they would find different subtypes of cells they already knew existed or would ... |
| May 17, 2018 | Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July | ATLANTA – May 17, 2018 – Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced the last patient, last visit in its 200-patient aceb... |
| Apr 13, 2017 | Polyphor raises CHF 40 million in financing round | |
| Nov 3, 2016 | Celtaxsys Announces Publication of Clinical Trial Results in Patients with Cystic Fibrosis | ATLANTA, GA–(Marketwired – November 03, 2016) – Celtaxsys, Inc., a clinical stage drug development company advancing therapies for patients with rare inflammatory diseases, announced today the publication of the second paper detailing the r... |
| Jun 4, 2015 | Celtaxsys Inc. Receives $5M Research Award to Advance Once Daily, Oral Anti-Inflammatory Medicine into Phase 2 CF Patient Lung Function Preservation Trial | ATLANTA, June 2, 2015 /PRNewswire/ — Celtaxsys, a clinicalstage drug development company focused on advancing care for patients sufferingfrom inflammatory diseases, including those with rare and orphan inflammatorydiseases, announced today ... |
| Feb 13, 2015 | UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy | Spyryx has more than $100,000, largely from angel investors, though it also has taken out a loan from the North Carolina Biotechnology Center. Spyryx is aiming to raise a Series A round and also study the drug’s efficacy in COPD, though it’... |
| Jan 6, 2015 | Venture philanthropy in healthcare is OK as long as black lives matter | The royalty sale is a huge win for the CFF, but this “venture philanthropy” move has raised a litany of concerns – as highlighted in Tuesday’s New York Times opinion piece. The privatization of medical research – and the subsidization of ph... |
| Sep 11, 2013 | Great Strides walk set for Saturday | SALAMANCA — Hundreds of St. Bonaventure University student-athletes, several teams and members of the Athletic Department will take part in the 8th Annual GREAT STRIDES: Taking Steps to Cure Cystic Fibrosis Walk on Saturday, Sept. 14, at St... |
| May 25, 2013 | Wow of the week: Surfers inspire device to treat cystic fibrosis | Dr. Richard Boucher, co-founder and chairman of Parion said: “We have seen evidence that routine exposure to salt water — but the challenge was to develop an optimal delivery system.” As Matthew Allen, program director at Cambridge Consulta... |
| May 16, 2013 | Cambridge firm uses next-generation DNA sequencing to detect more mutations in carrier screening | Carrier screening has been around for a while, and many women undergo screening before or during pregnancy for certain hereditary disorders associated with their ethnic background. The Associated Press in 2010 found that many inherited dise... |
| Mar 27, 2013 | An encouraged Savara Pharmaceuticals preps for phase 2 study of inhaled antibiotic for CF patients | MRSA has been growing in prevalence among CF patients and it’s also been associated with a quicker rate of decline in lung function.
Savara’s drug, AeroVanc, is a dry powder formulation of the antibiotic vancomycin, which is usually adminis... |
| Feb 28, 2013 | AHA expands venture philanthropy accelerator strategy to help life science startups survive | It is devising a strategy to increase donor engagement to smooth out the peaks and valleys and predict with some accuracy when it should do new rounds of investment because collaborating multiplies the value of each donor dollar. It shouldn... |
| Jun 14, 2012 | Drug developer with phase 3 cystic fibrosis treatment raising $40 million | South Plainfield, New Jersey-based PTC Therapeutics‘ drug Ataluren was given orphan drug status by the U.S. Food and Drug Administration and the European Commission to treat nonsense mutation cystic fibrosis and nonsense mutation Duchenne a... |
| Apr 30, 2012 | “Success” in the world of orphan drug development: it’s a matter of perspective | Earlier this month, Alexion Pharmaceuticals, Inc., reported the company’s first quarter results for 2012. According to the company’s press release, it had net product sales for the quarter of $244.7 million, based exclusively on sales of a ... |
| Dec 8, 2011 | 4 tips for life sciences companies seeking foundation funding | “Our job is to put the ball in the air, throw the long ball,” he said.
Angel investors and venture capitalists are not the only path for companies looking to traverse the so-called valley of death. Life sciences companies have a funding alt... |
| Jul 21, 2011 | Geek of the Week: Delane Hewett, DataSphere CTO | Delane Hewett, DataSphere (Annie Laurie Malarkey photo)
Our latest Geek of the Week, Delane Hewett, has been around the Seattle region’s tech community for years, at Boeing and then Microsoft, and now as the technology chief for fast-growin... |
| UNC spinout looking to one-up Kalydeco with one-size-fits-all cystic fibrosis therapy | Cystic fibrosis has become the poster child for precision medicine – most new therapies are carefully tailored to a CF patient’s genetic makeup. University of North Carolina spinout Spyryx Biosciences is proposing a one-size-fits-all approa... |
| American Airlines : 36th Annual Celebrity Ski Event Goes Virtual, Raising Critical Funds for the Cystic Fibrosis Foundation | FORT WORTH, Texas ― For 36 years, American Airlines has partnered with the Cystic Fibrosis Foundation to host Celebrity Ski Weekend. While this year's event shifted from the slopes of Beaver Creek, Colorado, to a virtual setting, the import... |
| Venture philanthropy in healthcare is OK as long as black lives matter | In this brave new world of drug development, we’re seeing philanthropic foundations intertwine with industry to bring meds faster to market. But this new model could unfold into a popularity contest, pitting underfunded disorders against me... |
| “Success” in the world of orphan drug development: it’s a matter of perspective | According to data from a variety of sources, there are between 6,500 and 7,000 disorders that meet the criterion for definition as an “orphan disease” here in the USA: a prevalence of < 200,000 patients living with the particular disorde... |
| The secret sauce of venture philanthropy: Passion and forced collaboration #CEDLSC15 | Last fall, all eyes darted to the concept of venture philanthropy – using venture dollars to empower patient advocacy efforts – when the Cystic Fibrosis Foundation sold its royalty rights to the Vertex drugs it funded for $3.3 billion.
A so... |
| AHA expands venture philanthropy accelerator strategy to help life science startups survive | A little more than a year ago the American Heart Association launched an accelerator to fund biotechnolgy and medical device startups to fill a crucial gap in research funding caused by the increasing hesitance of investors to risk support ... |
| An encouraged Savara Pharmaceuticals preps for phase 2 study of inhaled antibiotic for CF patients | Friday’s U.S. Food and Drug Administration approval of the TOBI Podhaler was great news for drugmaker Novartis and for the cystic fibrosis community. It was also welcome news for Texas drug startup Savara Pharmaceuticals, whose CEO Rob Nevi... |
| Cambridge firm uses next-generation DNA sequencing to detect more mutations in carrier screening | When a company sets out to enter a market inhabited by heavyweights like LabCorp and Quest Diagnostics, it better have something good. Good Start Genetics has applied next-generation DNA sequencing to existing knowledge and testing methods ... |
| 4 tips for life sciences companies seeking foundation funding | Max Wallace, CEO of Accelerate Brain Cancer Cure, uses a football analogy when explaining his foundation’s approach to funding life sciences research.
Large companies aren’t getting into the game, which they see as too risky. But the stakes... |
| Wow of the week: Surfers inspire device to treat cystic fibrosis | Surfers do some pretty awe-inspiring, jaw-dropping moves driven by a fearlessness of the water. And they have also inspired some significant scientific research. Observing surfers with cystic fibrosis spurred scientists to investigate wheth... |
